39 related articles for article (PubMed ID: 20238377)
1. Montelukast is a potent and durable inhibitor of multidrug resistance protein 2-mediated efflux of taxol and saquinavir.
Roy U; Chakravarty G; Honer Zu Bentrup K; Mondal D
Biol Pharm Bull; 2009 Dec; 32(12):2002-9. PubMed ID: 19952419
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir.
Sadler BM; Gillotin C; Lou Y; Eron JJ; Lang W; Haubrich R; Stein DS
Antimicrob Agents Chemother; 2001 Dec; 45(12):3663-8. PubMed ID: 11709366
[TBL] [Abstract][Full Text] [Related]
3. NADPH oxidase-generated reactive oxygen species are involved in estradiol 17ß-d-glucuronide-induced cholestasis.
Salas G; Litta AA; Medeot AC; Schuck VS; Andermatten RB; Miszczuk GS; Ciriaci N; Razori MV; Barosso IR; Sánchez Pozzi EJ; Roma MG; Basiglio CL; Crocenzi FA
Biochimie; 2024 Apr; 223():41-53. PubMed ID: 38608750
[TBL] [Abstract][Full Text] [Related]
4. Molecular Factors and Pathways of Hepatotoxicity Associated with HIV/SARS-CoV-2 Protease Inhibitors.
Ji C
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175645
[TBL] [Abstract][Full Text] [Related]
5. The inhibitory and inducing effects of ritonavir on hepatic and intestinal CYP3A and other drug-handling proteins.
Loos NHC; Beijnen JH; Schinkel AH
Biomed Pharmacother; 2023 Jun; 162():114636. PubMed ID: 37004323
[TBL] [Abstract][Full Text] [Related]
6. COVID-19-related liver injury: Focus on genetic and drug-induced perspectives.
Parchwani D; Sonagra AD; Dholariya S; Motiani A; Singh R
World J Virol; 2023 Jan; 12(1):53-67. PubMed ID: 36743658
[TBL] [Abstract][Full Text] [Related]
7. Drug-induced liver injury in COVID-19 treatment: Incidence, mechanisms and clinical management.
Li X; Wang W; Yan S; Zhao W; Xiong H; Bao C; Chen J; Yue Y; Su Y; Zhang C
Front Pharmacol; 2022; 13():1019487. PubMed ID: 36518661
[TBL] [Abstract][Full Text] [Related]
8. Drug-Induced Liver Injury in COVID-19 Patients: A Systematic Review.
Sodeifian F; Seyedalhosseini ZS; Kian N; Eftekhari M; Najari S; Mirsaeidi M; Farsi Y; Nasiri MJ
Front Med (Lausanne); 2021; 8():731436. PubMed ID: 34616757
[No Abstract] [Full Text] [Related]
9. Investigating the influence of relevant pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of orally administered docetaxel combined with ritonavir.
van Eijk M; Pluim D; Dorlo TPC; Marchetti S; Huitema ADR; Beijnen JH
Pharmacogenomics J; 2021 Jun; 21(3):336-345. PubMed ID: 33649517
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Drug Biliary Excretion Using Sandwich-Cultured Human Hepatocytes.
Fardel O; Moreau A; Le Vée M; Denizot C; Parmentier Y
Eur J Drug Metab Pharmacokinet; 2019 Feb; 44(1):13-30. PubMed ID: 30167999
[TBL] [Abstract][Full Text] [Related]
11. Exploring the Carbamazepine Interaction with Human Pregnane X Receptor and Effect on ABCC2 Using in Vitro and in Silico Approach.
Grewal GK; Singh KD; Kanojia N; Rawat C; Kukal S; Jajodia A; Singhal A; Misra R; Nagamani S; Muthusamy K; Kukreti R
Pharm Res; 2017 Jul; 34(7):1444-1458. PubMed ID: 28432535
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Adverse Drug Properties with Cryopreserved Human Hepatocytes and the Integrated Discrete Multiple Organ Co-culture (IdMOC(TM)) System.
Li AP
Toxicol Res; 2015 Jun; 31(2):137-49. PubMed ID: 26191380
[TBL] [Abstract][Full Text] [Related]
13. Effect of Ritonavir on (99m)Technetium-Mebrofenin Disposition in Humans: A Semi-PBPK Modeling and In Vitro Approach to Predict Transporter-Mediated DDIs.
Pfeifer ND; Goss SL; Swift B; Ghibellini G; Ivanovic M; Heizer WD; Gangarosa LM; Brouwer KL
CPT Pharmacometrics Syst Pharmacol; 2013 Jan; 2(1):e20. PubMed ID: 23887590
[TBL] [Abstract][Full Text] [Related]
14. Interaction between HIV protease inhibitors (PIs) and hepatic transporters in sandwich cultured human hepatocytes: implication for PI-based DDIs.
Liu L; Unadkat JD
Biopharm Drug Dispos; 2013 Apr; 34(3):155-64. PubMed ID: 23280499
[TBL] [Abstract][Full Text] [Related]
15. Complex drug interactions of HIV protease inhibitors 2: in vivo induction and in vitro to in vivo correlation of induction of cytochrome P450 1A2, 2B6, and 2C9 by ritonavir or nelfinavir.
Kirby BJ; Collier AC; Kharasch ED; Dixit V; Desai P; Whittington D; Thummel KE; Unadkat JD
Drug Metab Dispos; 2011 Dec; 39(12):2329-37. PubMed ID: 21930825
[TBL] [Abstract][Full Text] [Related]
16. Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors.
Griffin L; Annaert P; Brouwer KL
J Pharm Sci; 2011 Sep; 100(9):3636-54. PubMed ID: 21698598
[TBL] [Abstract][Full Text] [Related]
17. Use of antineoplastic agents in patients with cancer who have HIV/AIDS.
Rudek MA; Flexner C; Ambinder RF
Lancet Oncol; 2011 Sep; 12(9):905-12. PubMed ID: 21570912
[TBL] [Abstract][Full Text] [Related]
18. Interaction of eight HIV protease inhibitors with the canalicular efflux transporter ABCC2 (MRP2) in sandwich-cultured rat and human hepatocytes.
Ye ZW; Camus S; Augustijns P; Annaert P
Biopharm Drug Dispos; 2010 Mar; 31(2-3):178-88. PubMed ID: 20238377
[TBL] [Abstract][Full Text] [Related]
19. MRP2 Inhibition by HIV Protease Inhibitors in Rat and Human Hepatocytes: A Quantitative Confocal Microscopy Study.
Holmstock N; Oorts M; Snoeys J; Annaert P
Drug Metab Dispos; 2018 May; 46(5):697-703. PubMed ID: 29523599
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
